Psychedelic Drugs Research And Therapy Have Reached A ‘Turning Point’, Campaigners Say
December 30, 2016
Podcast
All
- All
Links
All
- All
Support
All
- All
BIPRP
All
- All
Science Talk
All
- All
Amanda's Talks
All
- All
- Video Talk
- Featured
- 2016 Onwards
- 2011-2015
- 2010 and Earlier
- Science Talk
- Policy Talk
One-pager
All
- All
Music
All
- All
Amanda Feilding
All
- All
Events
All
- All
Highlights
All
- All
Psilocybin for Depression
All
- All
Current
All
- All
Category
All
- All
- Science
- Policy
- Culture
Substance/Method
All
- All
- Opiates
- Novel Psychoactive Substances
- Meditation
- Trepanation
- LSD
- Psilocybin
- Cannabis/cannabinoids
- Ayahuasca/DMT
- Coca/Cocaine
- MDMA
Collaboration
All
- All
- Beckley/Brazil Research Programme
- Beckley/Maastricht Research Programme
- Exeter University
- ICEERS
- Beckley/Sant Pau Research Programme
- University College London
- New York University
- Cardiff University
- Madrid Computense University
- Ethnobotanicals Research Programme
- Freiburg University
- Medical Office for Psychiatry and Psychotherapy, Solothurn
- Beckley/Sechenov Institute Research programme
- Hannover Medical School
- Beckley/Imperial Research Programme
- King's College London
- Johns Hopkins University
Clinical Application
All
- All
- Depression
- Addictions
- Anxiety
- Psychosis
- PTSD
- Cancer
- Cluster Headaches
Policy Focus
All
- All
- Policy Reports
- Advisory Work
- Seminar Series
- Advocacy/Campaigns
Type of publication
All
- All
- Original research
- Report
- Review
- Opinion/Correspondence
- Book
- Book chapter
- Conference abstract
- Petition/campaign
Search type
AND
OR